| Trial ID: | L2949 |
| Source ID: | NCT01334229
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
|
| Acronym: |
JANUB48
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01334229/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period, 6 weeks | Secondary: Measurement of Glucagon-like Peptide-1 by ELISA, 6 weeks|Measurement of Glucose, 6 weeks|Measurement of Insulin, 6 weeks|Measurement of Apolipoprotein B48 and Apolipoprotein B100 Pool Sizes With Stable Isotope During Postprandial Period, 6 weeks|Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period, 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: Laval University | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-04
|
| Completion Date: |
2013-12
|
| Results First Posted: |
2014-09-10
|
| Last Update Posted: |
2016-04-04
|
| Locations: |
Laval University, Quebec, G1V 0A6, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01334229
|
